JP2016519165A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519165A5
JP2016519165A5 JP2016515318A JP2016515318A JP2016519165A5 JP 2016519165 A5 JP2016519165 A5 JP 2016519165A5 JP 2016515318 A JP2016515318 A JP 2016515318A JP 2016515318 A JP2016515318 A JP 2016515318A JP 2016519165 A5 JP2016519165 A5 JP 2016519165A5
Authority
JP
Japan
Prior art keywords
compound
compound according
methyl
nitrogen atoms
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016515318A
Other languages
English (en)
Japanese (ja)
Other versions
JP6506742B2 (ja
JP2016519165A (ja
Filing date
Publication date
Priority claimed from GBGB1309333.1A external-priority patent/GB201309333D0/en
Application filed filed Critical
Publication of JP2016519165A publication Critical patent/JP2016519165A/ja
Publication of JP2016519165A5 publication Critical patent/JP2016519165A5/ja
Application granted granted Critical
Publication of JP6506742B2 publication Critical patent/JP6506742B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016515318A 2013-05-23 2014-05-19 Wnt経路モジュレーターとしてのプリンジオン Active JP6506742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1309333.1 2013-05-23
GBGB1309333.1A GB201309333D0 (en) 2013-05-23 2013-05-23 Purine diones as WNT pathway modulators
PCT/SG2014/000217 WO2014189466A1 (en) 2013-05-23 2014-05-19 Purine diones as wnt pathway modulators

Publications (3)

Publication Number Publication Date
JP2016519165A JP2016519165A (ja) 2016-06-30
JP2016519165A5 true JP2016519165A5 (enExample) 2017-04-06
JP6506742B2 JP6506742B2 (ja) 2019-04-24

Family

ID=48784655

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016515318A Active JP6506742B2 (ja) 2013-05-23 2014-05-19 Wnt経路モジュレーターとしてのプリンジオン

Country Status (13)

Country Link
US (6) US9926320B2 (enExample)
EP (1) EP2999699B1 (enExample)
JP (1) JP6506742B2 (enExample)
KR (2) KR102153989B1 (enExample)
CN (2) CN109776537B (enExample)
AU (2) AU2014269134B2 (enExample)
BR (1) BR112015029182B1 (enExample)
CA (1) CA2912757C (enExample)
DK (1) DK2999699T3 (enExample)
ES (1) ES2802923T3 (enExample)
GB (1) GB201309333D0 (enExample)
SG (1) SG11201509593TA (enExample)
WO (1) WO2014189466A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
GB201322334D0 (en) 2013-12-17 2014-01-29 Agency Science Tech & Res Maleimide derivatives as modulators of WNT pathway
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
DK3193880T3 (da) * 2014-09-19 2020-06-02 Lilly Co Eli Hæmning af den transiente receptor-potential-A1-ionkanal
CN105440034B (zh) * 2015-11-16 2017-08-15 山东罗欣药业集团股份有限公司 一种利格列汀及其中间体的制备方法
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN106632332B (zh) * 2016-09-26 2018-07-06 杭州新博思生物医药有限公司 一种伊曲茶碱的制备方法
WO2019054941A1 (en) 2017-09-14 2019-03-21 Agency For Science, Technology And Research MODULATORS OF THE WNT PATH
CA3088551C (en) 2018-01-31 2023-01-24 Eli Lilly And Company Inhibiting the transient receptor potential a1 ion channel
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
WO2020069344A1 (en) 2018-09-28 2020-04-02 Children's Medical Center Corporation Treating atopic dermatitis by targeting the wnt pathway
CN114072131B (zh) * 2019-05-22 2024-03-19 新加坡科技研究局 口服制剂、其制备方法及其用途
US20220211715A1 (en) * 2019-05-22 2022-07-07 Agency For Science, Technology And Research Pharmaceutical combination
US12365686B2 (en) * 2019-07-08 2025-07-22 Jiangsu Kanion Pharmaceutical Co., Ltd. Compound as porcupine inhibitor and use thereof
JP2023511039A (ja) * 2020-01-08 2023-03-16 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 組み合わせ療法
WO2022270994A1 (ko) 2021-06-25 2022-12-29 한국화학연구원 유비퀴틴 프로테오좀 경로를 통해 비티케이 분해작용을 가지는 신규한 이작용성 헤테로사이클릭 화합물과 이의 용도
WO2023072263A1 (zh) * 2021-10-29 2023-05-04 南京明德新药研发有限公司 5-取代的吡啶-2(1h)-酮类化合物及其应用
CN114671875A (zh) * 2022-04-27 2022-06-28 成都施贝康生物医药科技有限公司 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途
CN120737092B (zh) * 2025-09-05 2025-11-14 利诚检测认证集团股份有限公司 别嘌醇半抗原及其制备方法、人工抗原、抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AU2006327181A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
CN101801362B (zh) * 2007-06-22 2014-01-22 海德拉生物科学公司 用于治疗病症的方法和组合物
SG185942A1 (en) * 2007-11-02 2012-12-28 Agency Science Tech & Res Methods and compounds for preventing and treating a tumour
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009140519A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010036821A1 (en) * 2008-09-24 2010-04-01 Hydra Biosciences, Inc. Methods and compositions for treating respiratory disorders
WO2010075353A1 (en) 2008-12-22 2010-07-01 Hydra Biosciences, Inc. Compositions useful for treating disorders related to trpa1
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
EP2655377B1 (en) 2010-12-20 2016-03-30 Glenmark Pharmaceuticals S.A. 2-amino-4-arylthiazole compounds as trpa1 antagonists
WO2012172475A1 (en) * 2011-06-13 2012-12-20 Glenmark Pharmaceuticals S.A. Treatment of respiratory disorders using trpa1 antagonists
JP5659098B2 (ja) * 2011-07-19 2015-01-28 株式会社東芝 半導体装置の製造方法
WO2013014597A1 (en) * 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
MX2014001551A (es) 2011-08-09 2014-09-15 Hydra Biosciences Inc Inhibicion de canal ionico del potencial receptor transitorio a1 (trpa1).
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
CN104640856B (zh) 2012-05-11 2017-09-15 复位治疗公司 作为隐花色素调节剂的含有咔唑的磺酰胺类
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators

Similar Documents

Publication Publication Date Title
CA2903288C (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP2015531773A5 (enExample)
JP2015537020A5 (enExample)
JP2016530259A5 (enExample)
JP2015509535A5 (enExample)
PH12019502370A1 (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
JP2013010792A5 (enExample)
JP2016510323A5 (enExample)
JP2013532652A5 (enExample)
JP2014507455A5 (enExample)
JP2015535839A5 (enExample)
JP2014511892A5 (enExample)
JP2016518437A5 (enExample)
RU2012112050A (ru) Производные дигидроптеридинона, способ их получения и фармацевтическое применение
JP2010523522A5 (enExample)
JP2016529319A5 (enExample)
JP2018529690A5 (enExample)
JP2017524733A5 (enExample)
JP2015508092A5 (enExample)
JP2014513051A5 (enExample)
JP2016537382A5 (enExample)
JP2016529315A5 (enExample)
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
JP2016528273A5 (enExample)
JP2015502371A5 (enExample)